Journal article
Structure-activity studies reveal scope for optimisation of Ebselen-type inhibition of SARS-COV-2 main protease
- Abstract:
-
The reactive organoselenium compound ebselen is being investigated for treatment of coronavirus disease 2019 (COVID-19) and other diseases. We report structure-activity studies on sulfur analogues of ebselen with the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro), employing turnover and protein-observed mass spectrometry-based assays. The results reveal scope for optimisation of ebselen/ebselen derivative- mediated inhibition of Mpro, particularly with respect to improved selectivity.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 2.6MB, Terms of use)
-
- Publisher copy:
- 10.1002/cmdc.202100582
Authors
- Publisher:
- Wiley
- Journal:
- ChemMedChem More from this journal
- Volume:
- 17
- Issue:
- 4
- Article number:
- e202100582
- Publication date:
- 2021-12-27
- Acceptance date:
- 2021-12-02
- DOI:
- EISSN:
-
1860-7187
- ISSN:
-
1860-7179
- Language:
-
English
- Keywords:
- Pubs id:
-
1341495
- Local pid:
-
pubs:1341495
- Deposit date:
-
2023-05-18
- ARK identifier:
Terms of use
- Copyright holder:
- Thun-Hohenstein et al.
- Copyright date:
- 2021
- Rights statement:
- © 2021 The Authors. ChemMedChem published by Wiley-VCH GmbH This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record